

Ant
F 1x

http://rex.nci.nih.gov/NCI_Pub_Interface/raterisk/ratestoc.html). While surgery can often provide definitive treatment of cancer in its early stages, the eradication of metastases is crucial to the cure of more advanced disease. Chemotherapeutic drugs are used in combinations for this purpose, with considerable success. Nonetheless, over half a million Americans will die from cancer this year. Progressions and relapses following surgery and chemotherapy/radiation are not uncommon, and in most cases the second line of treatment is of limited use. Despite the expenditure of large amounts of public and private resources over many years, better treatments for cancer are sorely needed.

IN THE CLAIMS:

✓ Please cancel claims 39-41 without prejudice.

Please add new claims 42 and 43.

42. (New) A mutant antibody comprising a reactive site not present in the wild-type of said antibody and a complementarity-determining region (CDR) that specifically binds a metal chelate, wherein said reactive site is in a position proximate to or within said complementarity-determining region.

C 2
Ant
F 7

43. (New) A mutant antibody comprising a reactive site not present in the wild-type of said antibody and a complementarity-determining region (CDR) that recognizes a metal chelate comprising a reactive group or portions thereof, wherein said reactive site is in a position proximate to or within said complementarity-determining region, and

wherein said reactive group has complementary reactivity to said reactive site of said antibody.

Please amend claims 1, 10, 18, and 25 as follows:

C 3
Ant
F 3

1. (Once amended) A mutant antibody comprising a reactive site not present in the wild-type of said antibody and a complementarity-determining region

MPA
(CDR) that recognizes a metal chelate or portions thereof, wherein said reactive site is in a position proximate to or within said complementarity-determining region.

C 4
10. (Once amended) A polypeptide comprising a peptide sequence according to SEQ. ID NO.:5 (FIG. 12).

18. (Once amended) The mutant antibody according to claim 17, having the structure:

Ab-L-T

C 5
wherein,

Ab represents said antibody;

L is a chemical bond or linking group; and

T is said targeting moiety.

C 6
MPA
KV
25. (Twice amended) A mutant antibody comprising a cysteine residue not present in the wild-type of said antibody and a complementarity-determining region that recognizes a metal chelate or portions thereof, wherein said cysteine is in a position proximate to or within said complementarity-determining region.

REMARKS

The Invention

The present invention is directed to a mutant antibody comprising a reactive site not present in the wild-type of said antibody and a complementarity-determining region (CDR) that recognizes a metal chelate. The reactive site is in a position proximate to or within said complementarity-determining region.

Status of the Claims

After entry of this amendment, claims 1-3, 10-11, 14-25, and 30-41 are pending in the above-referenced patent application. Claims 10 and 11 are deemed to be in condition for allowance. Applicants acknowledge and appreciate the Examiner's statement that claims 10 and 11 are allowable. Claims 39-41 have been canceled without